Pharmasset, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 19   

Articles published

VRUS 0.0000
price chart
3 Reasons Merck & Co., Inc.'s Stock Could Fall
While other companies have had success buying clinical-stage hepatitis C drugs -- just look at Gilead Sciences' $11 billion purchase of Pharmasset, which yielded the now-blockbuster drug Sovaldi -- Idenix's pipeline has been riddled with ...
Related articles »  
Gilead: Let's Make A Deal
The driver for this rapid growth for GILD was the acquisition of Pharmasset for $11 billion in late 2011, which seemed at the time to be an outrageous price for a company with no marketed drugs.
Hot Stocks Alert: Gilead Sciences Inc. (NASDAQ:GILD), Achillion ...  Market News Call
Related articles »  
Gilead Says Wins Favorable Ruling On Hepatitis C Drug
Roche initiated arbitration proceedings against Gilead in 2013, asserting exclusive rights over sofosbuvir by virtue of its 2004 collaboration agreement with Pharmasset Inc. Gilead bought Pharmasset in 2012. Gilead started selling sofosbuvir under the ...
Gilead wins critical Sovaldi legal fight, Roche finds consolation  MarketWatch (blog)
Related articles »  
Traders Favorite: Gilead Sciences Inc. (NASDAQ:GILD), Achillion ...
Roche initiated arbitration proceedings against Gilead in 2013, asserting exclusive rights over sofosbuvir by virtue of its 2004 collaboration agreement with Pharmasset Inc. Gilead bought Pharmasset in 2012. Gilead started selling sofosbuvir under the ...
Related articles »  
Market Movers: Barrick Gold (NYSE:ABX), Gilead Sciences (NASDAQ:GILD ...
Roche initiated arbitration proceedings against Gilead in 2013, asserting exclusive rights over sofosbuvir by virtue of its 2004 collaboration agreement with Pharmasset Inc. Gilead bought Pharmasset in 2012. Gilead started selling sofosbuvir under the ...
Gilead Sciences: Despite This Year's Triumphs, Watch Out For Weaknesses - An ...
In 2011, GILD's acquisition of Pharmasset took the company to even greater heights - Forbes called the move "one of the best pharma acquisitions ever"; nearly single-handedly, buying Pharmasset propelled Gilead forward, making it the number four ranked ...
Related articles »  
3 Reasons Gilead Science, Inc.'s Stock Could Rise
Investors should have a lot of confidence in management's strategy after the acquisition of Pharmasset, which brought Sovaldi to Gilead.
Volume Alert: Gilead Sciences Inc. (NASDAQ:GILD), MannKind Corporation ...  Market News Call
Related articles »  
Notable 52-Week Highs and Lows of the Day 8/15: (ACHN) (GILD) (BITA) High ...
Gilead disclosed the following on Friday: In March 2013, Roche initiated an arbitration against us and Pharmasset, predecessor to Gilead Pharmasset LLC, regarding a 2004 collaboration agreement between Roche and Pharmasset. ... Bitauto Holdings ...
Achillion's hepatitis C drug shows promise in trial  Reuters UK
Related articles »  
Should Achillion Pharma (ACHN) Be In Your Portfolio Now?
Achillion Pharmaceuticals Inc. (ACHN) is a biopharmaceutical firm that researches, develops, and sells treatments and cures for infectious diseases.
Alzheon Appoints Renowned Industry Leader, Jean-Pierre Sommadossi, PhD, to ...
Dr. Sommadossi is the principal founder of Idenix Pharmaceuticals, Inc. IDIX and a co-founder of Pharmasset, Inc. Both of these companies were acquired; Idenix by Merck for $3.85 billion in 2014, and Pharmasset by Gilead for $11.1 billion in 2012.
Related articles »